Independent treatment guide
Vaginal laser, radiofrequency and focused ultrasound
“Vaginal tightening” groups together different symptoms and devices that should not share one promise. Controlled findings for laser and radiofrequency are inconsistent, direct intimate-HIFU evidence is sparse, and dryness, pain, continence or prolapse concerns may need diagnosis-led care instead.
Start here
Lasers, radiofrequency and focused-ultrasound devices deliver energy to vaginal or vulval tissue in different ways. They are marketed for “laxity”, dryness, pain during sex, urinary leakage, sexual function or menopausal symptoms—different concerns that should not be bundled together.
Dryness, pain, bleeding, a bulge, urinary symptoms and sexual concerns can have medical, hormonal, pelvic-floor or psychosocial causes. A cosmetic package should not replace diagnosis or established options such as pelvic-floor care, lubricants, moisturisers or clinically appropriate vaginal oestrogen.
HIFU deserves particular care in interpretation. Focused ultrasound is used medically to ablate selected tissue, including in some gynaecological research. That does not prove cosmetic “tightening”: a study treating a precancerous vaginal lesion or vulval disorder has a different target, dose and outcome from a device marketed for laxity or incontinence.
Do not start by choosing laser, RF or HIFU. Start with the symptom and diagnosis. The evidence is not strong enough to treat these devices as interchangeable upgrades over established care.
What it may help with
What it will not do
Compare technologies carefully
“Energy-based treatment” is a useful umbrella for safety discussions, but too broad for deciding whether a particular device works for a particular symptom.
CO₂ or Er:YAG energy
Creates controlled thermal injury with claims around menopausal symptoms, tissue quality, laxity or continence.
For genitourinary symptoms of menopause, controlled reviews find little to no difference for several outcomes versus sham or vaginal oestrogen. NICE says use only in a randomised trial.
That NICE recommendation is specific to menopausal genitourinary symptoms. It should not be distorted into either “all vaginal laser is banned” or “laser is proven for every other claim”.
Controlled tissue heating
Heats tissue more diffusely than focused ultrasound, with claims involving laxity, sexual function and urinary symptoms.
Small sham-controlled studies exist, but results, devices and outcomes vary. A 2024 review found observational gains were not consistently reproduced when randomised evidence was isolated.
Short follow-up and limited adverse-event reporting leave uncertainty about durability and uncommon harms.
Focused ultrasound at selected depths
Marketed to create focal thermal zones for “tightening”, sexual concerns or urinary symptoms.
A retrospective incontinence analysis is not enough to establish comparative benefit. Medical HIFU studies for vaginal lesions or vulval disease cannot be repurposed as evidence for rejuvenation.
Ask for the exact device, intended use, focal depth and controlled evidence. Internal anatomy and symptom diagnosis make generic salon protocols particularly difficult to justify.
Non-device and specialist options
Match treatment to dryness, GSM, pelvic-floor dysfunction, prolapse, incontinence, pain, skin disease or another cause.
Options may include no treatment, lubricants, moisturisers, vaginal oestrogen, pelvic-floor physiotherapy, continence care or gynaecology/urogynaecology input.
Unexplained bleeding, discharge, pain, a bulge or urinary difficulty should be assessed rather than packaged as “laxity”.
Results & trade-offs
Evidence for menopausal dryness cannot be transferred to laxity, sexual function or incontinence. Ask what exact symptom the treatment is intended to change.
CO₂ laser, Er:YAG laser, radiofrequency and HIFU have different energy delivery and cannot borrow one another’s results.
A 2024 review found apparent gains in observational studies, but vaginal-laxity improvements were not demonstrated when randomised trials were isolated.
Trials often have limited follow-up and inconsistent adverse-event reporting, so absence of reported serious harm is not proof of long-term safety.
Research in context
Controlled results for laser and radiofrequency are inconsistent, direct intimate-HIFU evidence is sparse, and adverse-event follow-up is limited. NICE restricts vaginal laser for menopausal genitourinary symptoms to randomised trials.
Optimistic observational studies conflict with more cautious sham-controlled and guideline conclusions. Laser has the largest evidence base but remains uncertain for several symptoms; RF evidence is smaller; direct cosmetic intimate-HIFU evidence is thinner again.
Safety
“Non-surgical” does not mean risk-free. The exact device or product, treatment area, practitioner and your health all change the risk.
If you feel seriously unwell or have trouble breathing, seek urgent medical help. This page cannot assess an individual complication.
Suitability
The treatment journey
Describe what is happening, when it began and its impact. “Tightening” is not enough to select safe care.
A suitably qualified clinician should assess hormonal, pelvic-floor, dermatological, urinary, prolapse and other possible causes, and investigate red flags.
Depending on the diagnosis, options can include no treatment, lubricants, moisturisers, pelvic-floor physiotherapy, vaginal oestrogen or specialist care.
For laser, RF or HIFU, ask for exact-device evidence for the diagnosed symptom, the regulator and manufacturer’s intended use, safeguards, validated outcomes and long-term follow-up.
Compare your options
Non-hormonal options that can help dryness or discomfort; choose based on the actual symptom.
NICE-recommended for genitourinary menopausal symptoms for many people, after an individual discussion.
Evidence-based assessment and rehabilitation for selected pelvic-floor and continence concerns.
Appropriate for pain, bleeding, prolapse, recurrent symptoms, complex history or uncertain diagnosis.
Take this to your consultation
What diagnosis explains my symptom, and what red flags have been excluded?
What does NICE recommend for this exact concern?
What established non-device options are available to me?
Is this treatment part of a registered randomised controlled trial?
Is this CO₂ laser, Er:YAG laser, radiofrequency or HIFU, and what evidence supports that exact device for my diagnosed symptom?
Who is medically accountable if I develop a burn, scar, pain or infection?
How long is follow-up, and what is known about durability and long-term harm?
Source library
We link to guidance and papers so you can check the evidence yourself. A source appearing here does not mean every claim or conclusion in it is beyond debate.
National Institute for Health and Care Excellence
Says not to offer vaginal laser for menopausal genitourinary symptoms outside a randomised controlled trial.
National Institute for Health and Care Excellence
Explains the small evidence base, potential harm such as scarring, and lack of cost effectiveness.
Menopause / PMC
Found little to no difference for several CO₂-laser outcomes versus sham or vaginal oestrogen and very uncertain evidence elsewhere.
American Journal of Obstetrics & Gynecology / PubMed
Observational improvement was not reproduced when randomised trials were considered separately.
International Urogynecology Journal / PubMed
Latest review located; says evidence is mainly observational with substantial bias and calls for larger high-quality RCTs.
Cochrane review / PubMed
Nine trials found uncertain evidence and little to no short-term difference in continence versus sham; few studies followed participants beyond one year.
PubMed
Retrospective analysis without the comparative design needed to establish how HIFU performs against sham or established care.
International Journal of Hyperthermia / PubMed
Small retrospective disease-treatment study included to show why medical lesion evidence must not be repurposed as proof of cosmetic tightening.
Common questions
It has no single medical definition. Clinics may use it for laxity, dryness, painful sex, urinary symptoms or appearance. Those concerns have different causes and treatments, so diagnosis comes first.
NICE’s 2024 menopause recommendation says not to offer vaginal laser for genitourinary symptoms associated with menopause unless it is part of a randomised controlled trial.
No. Devices, energy patterns and indications differ. Laser has more published research, but controlled results remain uncertain for several symptoms; RF evidence is smaller and direct cosmetic intimate-HIFU evidence is especially sparse.
No. HIFU studied for a diagnosed lesion such as vaginal intraepithelial neoplasia targets diseased tissue. That cannot validate claims about laxity, sexual function or continence.
NICE discusses vaginal oestrogen and non-hormonal lubricants or moisturisers. The right choice depends on your symptoms, preferences and medical history.
Seek assessment for unexplained bleeding, severe or persistent pain, offensive discharge, fever, a new bulge, difficulty urinating or symptoms that worsen after treatment.
Clinic directory
Directory information is separate from our editorial assessment. Inclusion is not a medical endorsement.
11 clinics
